昂利康：布比卡因获批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for the chemical raw material drug Bupivacaine, enhancing its product line and core competitiveness [1] Summary by Relevant Categories Regulatory Approval - The company submitted the drug registration application for Bupivacaine in December 2023, which was accepted in January 2024, and has now received the approval notice [1] Product Information - Bupivacaine is primarily used for local anesthesia and postoperative analgesia, indicating its significance in clinical applications [1] Strategic Implications - The approval of Bupivacaine will further enrich the company's product portfolio, thereby improving its competitive edge in the market [1]